SLC6A3 and Parkinson disease: Consistently, this work found that patients with PD-pRBD+ exhibited a more rapid decline in striatal dopamine transporter binding and cognition, greater daytime sleepiness, and worse disease staging than patients with PD-pRBD− as the disease progressed.